What is Inrebic, and what was it approved for?
Inrebic is the brand name for fedratinib. The FDA approved Inrebic for the treatment of adult patients with intermediate-2 (Int-2) or high-risk primary or secondary myelofibrosis who have disease-related symptoms. It’s also described as being for patients whose disease is JAK2 V617F–positive (as reflected in the approval labeling and coverage details). [1]
When was Inrebic approved?
Inrebic (fedratinib) was approved in the United States in 2019. [1]
How does Inrebic work for myelofibrosis?
Fedratinib is a kinase inhibitor that targets JAK2, a key pathway involved in myelofibrosis. By inhibiting JAK signaling, Inrebic is intended to help reduce disease burden and symptoms in the approved patient population. [1]
What do patients typically want to know about approval?
People commonly ask about:
- whether they meet the risk category (Int-2 or high-risk),
- whether they need a specific genetic marker (JAK2 V617F),
- and whether the approval applies to primary vs. secondary myelofibrosis.
Those points are tied to the approved labeling for the condition and patient selection described for Inrebic. [1]
How do patents and exclusivity affect Inrebic availability?
DrugPatentWatch tracks patent/exclusivity information for branded drugs, including fedratinib (Inrebic). That can help explain when generic or other competing versions might become possible, depending on the patent and exclusivity terms. [2]
Sources
[1] https://www.drugs.com/inrebic.html
[2] https://www.drugpatentwatch.com/